Walgreens helps underwrite CDC Foundation's HIV research

Press enter to search
Close search
Open Menu

Walgreens helps underwrite CDC Foundation's HIV research

By Michael Johnsen - 09/07/2017

DEERFIELD, Ill. — Following last year’s impactful collaboration between Walgreens and the CDC Foundation addressing the Zika outbreak, the two organizations on Wednesday announced they are once again working together to help address another public health challenge — this time HIV prevention.

To help extend the CDC Foundation’s important research and demonstration project, Walgreens made a donation to help fund the CDC Foundation’s Sustainable Healthcenter Implementation PrEP Pilot study. PrEP is a medication protocol for people who do not have HIV to help proactively protect against HIV infection.


To help address the spread of HIV/AIDS, the SHIPP study aims to answer important health services implementation questions about the delivery, outcomes, cost and sustainability of PrEP when provided as a clinical prevention service in community settings. For the purpose of best practices which can be sustained, replicated and scaled across communities, PrEP is being administered by providers using procedures representative of real world use.


“We are very grateful to Walgreens for stepping forward during the early days of the Zika response, and more recently, for their contributions to help prevent the spread of HIV and AIDS through support of our SHIPP study,” stated Judith Monroe, president and CEO of the CDC Foundation. “Integrating PrEP as a prevention strategy has the capability to change the course of the HIV/AIDS epidemic, but first we must better understand how to increase access, uptake and medication adherence.”


According to CDC data, when taken consistently, PrEP has been shown to reduce the risk of HIV infection in people who are at high risk by more than 90%. Seen to its completion, the SHIPP study will be a significant and much–needed contribution to the evidence base for future decision-making around PrEP delivery in the United States.


“With a decades-long commitment to the HIV community, at Walgreens we recognize the important role that pharmacies play in addressing the nationwide HIV/AIDS epidemic,” commented Glen Pietrandoni, senior director of patient care and advocacy for Walgreens. “Supporting the CDC Foundation and its SHIPP study is another way, in addition to providing our patients with HIV testing services as well as medication, for us to contribute to the research and advancement in HIV prevention and treatment. ... Collaborations like the two we have embarked on with the CDC Foundation play a vital role in getting important health messages out to key audiences," he said. "After experiencing the positive outcomes that arose from working together on last year’s Zika outbreak, we saw tremendous potential in working with them to help address the HIV/AIDS health challenge.”


The 2016 Zika outbreak presented urgent and unique challenges for many high-risk areas and groups around the world, including communicating how to prevent Zika transmission. The CDC Foundation activated its emergency response fund in early 2016 to assist the Centers for Disease Control and Prevention during the Zika response. Immediately following this activation, Walgreens joined as one of the first partners in the Zika response for the CDC Foundation, including support for communications activities as well as implementing their own in-store efforts to educate pregnant women in high-risk areas about how to protect themselves and their unborn children from Zika. Specifically, in its stores in Puerto Rico, Walgreens dedicated high-traffic space to providing information on CDC-recommended steps to prevent the spread of Zika virus.